JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT

Mechelen, Belgium; 18 January 2022; 22.01 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the Medicines and Healthcare products...

Related Keywords

United Kingdom ,Mechelen ,Region Flamande ,Belgium ,Japan ,Northern Ireland ,Craigavon ,Japanese ,Great Britain ,Van Gijsel ,Sandra Cauwenberghs ,Marieke Vermeersch ,Anna Gibbins ,Ian Beales ,Michele Manto ,Ruth Wakeman ,Norwich University Hospital ,European Commission ,Gilead Sciences Inc ,Therapeutic Areas Communications ,Regulatory Agency ,Japanese Ministry Of Health ,European Union ,Devices Agency ,Japan Pharmaceuticals ,Chief Commercial Officer ,General Medicine ,Chief Investigator ,Colitis United Kingdom ,Medical Devices Agency ,Great Britain Summary ,Product Characteristics ,Northern Ireland Summary ,European Summary ,Japanese Ministry ,Gilead Sciences ,Brussels Stock Exchange Glpg ,Galapagos Nv ,